RxDoctor Payments Data

Samuel Fadare, MD

Psychiatry · Gladstone, MONPI 1184685802

Payments from drug & device makers

$7,607in general payments, 2019–2025

Across 388 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • Lundbeck LLC$616
  • Alkermes, Inc.$478
  • Neurocrine Biosciences, Inc.$445
  • plus $2K from 10 others

What the payments were for

  • Food & beverage$7,40797%
  • Education$2003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,607 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$5,093
Medicare patients
17
Services billed
40

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine14$88,180
RexultiBrexpiprazole17$32,659
LybalviOlanzapine/Samidorphan Malate11$20,252
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine59$1,604
Vilazodone Hcl13$1,190
Armodafinil14$908
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$901
Venlafaxine Hcl ErVenlafaxine Hcl38$753
Gabapentin48$714
Methadone Hcl12$707
Clonazepam117$674
Olanzapine22$582
Lamotrigine18$492
Zolpidem Tartrate38$395
Trazodone Hcl59$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$423$88,18014 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,333$32,65917 claims
Alkermes, Inc.Lybalvi$478$20,25211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Gladstone

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →